New cocktail of cancer drugs shows promise in early trial
NCT ID NCT06806852
First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 7 times
Summary
This study tests whether combining three different antibodies—BI 770371, pembrolizumab, and cetuximab—can shrink tumors in people with head and neck cancer that has spread or come back. About 91 adults are randomly assigned to one of three treatment groups. The goal is to see if the combinations are safe and effective compared to pembrolizumab alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 770371, pembrolizumab, and cetuximab (antibodies given as infusions)
- What this could lead to
- If successful, this could lead to a more effective first-line treatment for metastatic or recurrent head and neck cancer, potentially shrinking tumors and improving outcomes.
- What could go wrong
- This is an early phase 1 trial with only 91 participants, so results may not apply to everyone. The combination of drugs may cause side effects or not work better than standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
"Prof. Dr. Alexandru Trestioreanu" Oncology Institut
Bucharest, 022328, Romania
-
ARENSIA Exploratory Medicine
Chisinau, MD-2025, Moldova
-
ARENSIA Exploratory Medicine LLC
Tbilisi, 0112, Georgia
-
Abdurrahman Yurtaslan Oncology Training and Research Hospital
Ankara, 06200, Turkey (Türkiye)
-
Adana City Hospital
Adana, 01220, Turkey (Türkiye)
-
Andrew Love Cancer Centre
Geelong, Victoria, 3220, Australia
-
Ankara Bilkent City Hospital
Ankara, 06800, Turkey (Türkiye)
-
Azienda Ospedaliera Universitaria Integrata Verona
Verona, 37126, Italy
-
CTR Leon Berard
Lyon, 69373, France
-
CTR Oscar Lambret
Lille, 59020, France
-
Cantonspital Aarau
Aarau, 5001, Switzerland
-
Center of Oncology of the Lublin Region St. Jana z Dukli
Lublin, 20090, Poland
-
Centro Oncologico Personalizado
México, 06760, Mexico
-
Centro Oncológico Internacional
Tlajomulco de Zuñiga, 45640, Mexico
-
Clinexpert Gyongyos
Gyöngyös, 3200, Hungary
-
Fundação Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto, 15090-000, Brazil
-
Gosford Hospital
Gosford, New South Wales, 2250, Australia
-
HOP Timone
Marseille, 13385, France
-
Hacettepe University Oncology Hospital
Ankara, 06230, Turkey (Türkiye)
-
Hokkaido University Hospital
Hokkaido, Sapporo, 060-8648, Japan
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital de Amor
Barretos, 14784-400, Brazil
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Instituto Nacional de Cancerologia
México, 14080, Mexico
-
Istanbul University Medical Faculty Capa Hospital
Istanbul, 34093, Turkey (Türkiye)
-
Istituto Scientifico Romagnolo
Meldola (FC), 47014, Italy
-
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, 135-8550, Japan
-
Kansai Medical University Hospital
Osaka, Hirakata, 573-1191, Japan
-
Kobe University Hospital
Hyogo, Kobe, 650-0017, Japan
-
Liga Norte Riograndense contra o cancer
Natal, 59062-000, Brazil
-
M Health Fairview Clinics and Surgery Center - Minneapolis
Minneapolis, Minnesota, 55455, United States
-
MBAL Sveta Sofia
Sofia, 1404, Bulgaria
-
National Taiwan University Hospital
Taipei, 10048, Taiwan
-
National University Hospital-Singapore-22806
Singapore, 119228, Singapore
-
Norton Cancer Institute, Downtown
Louisville, Kentucky, 40202, United States
-
Samsung Medical Center
Seoul, 135-710, South Korea
-
Semmelweis University
Budapest, 1083, Hungary
-
Severance Hospital
Seoul, 03722, South Korea
-
Shizuoka Cancer Center
Shizuoka, Sunto-gun, 411-8777, Japan
-
Siriraj Hospital
Bangkoknoi, 10700, Thailand
-
St Bartholomew's Hospital
London, EC1A 7BE, United Kingdom
-
Städtisches Klinikum Braunschweig gGmbH
Braunschweig, 38114, Germany
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
-
The Catholic University of Korea, St.Vincent's Hospital
Suwon, 16247, South Korea
-
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
The Royal Marsden Hospital, Chelsea
London, SW3 6JJ, United Kingdom
-
The Royal Marsden Hospital, Sutton
Sutton, SM2 5PT, United Kingdom
-
Unidad Clinica Farmacologica Bioemagno
Mexico City, 04660, Mexico
-
Universität Leipzig
Leipzig, 04103, Germany
-
Universitätsklinikum Jena
Jena, 07743, Germany
-
Universitätsklinikum Ulm
Ulm, 89081, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?